| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Benzodiazepines represent a large family of medications used to treat a wide range of disorders, from anxiety to seizures. They also are used in pain management. With a high risk for abuse and diversion, professional practice guidelines recommend compliance monitoring for these medications using urine drug tests. However, traditional benzodiazepine immunoassays suffer from a lack of cross-reactivity with many benzodiazepines.
Benzodiazepine test menu
Our targeted, high-resolution mass spectrometry screening assay identifies 27 different benzodiazepines and metabolites in the urine, reducing the need for additional confirmation assays. Results of this assay enable clinicians to accurately detect recent benzodiazepine use and effectively monitor treatment compliance.
Key testing
Highlights
In this “Hot Topic,” Paul Jannetto, Ph.D., highlights Mayo Clinic’s targeted benzodiazepine assay and discusses the advantages and limitations of various urine-screening assays as well as quantitative confirmatory testing to determine compliance to benzodiazepine therapy.
Several of our comprehensive profiles include targeted benzodiazepine monitoring (Mayo ID: TABSU).
Panel testing
Key testing